Supplementary Table 1 Treatment-related adverse events (*n* = 102)

Adverse events	Grade 1-2	Grade 3-4
Any treatment-related adverse events	62 (60.78)	33 (32.35)
Asthenia	44 (43.14)	4 (3.92)
Hand-foot syndrome	28 (27.45)	5 (4.90)
Hypertension	27 (26.47)	7 (6.86)
Decreased white blood cells	25 (24.51)	5 (4.90)
Rash	23 (22.55)	6 (5.88)
Decreased platelet count	22 (21.57)	4 (3.92)
Proteinuria	19 (18.63)	1 (0.98)
Decreased appetite	16 (15.69)	0
Fever	15 (14.71)	1 (0.98)
Increased aspartate aminotransferase	13 (12.75)	5 (4.90)
Increased alanine aminotransferase	11 (10.78)	5 (4.90)
Vomiting	11 (10.78)	0
Pruritus	9 (8.82)	0
Bone pain	8 (7.84)	0
Diarrhea	7 (6.86)	3 (2.94)
Increased blood thyroid-stimulating hormone	6 (5.88)	2 (1.96)
Nausea	7 (6.86)	0
Bleeding gum	4 (3.92)	0
Gastrointestinal hemorrhage	3 (2.94)	2 (1.96)
Canker sore	3 (2.94)	0
Hair loss	3 (2.94)	0

Supplementary Table 2 Subsequent treatment after transarterial chemoembolization + lenvatinib + PD-1 combination

Treatment	Total (n = 102)
No subsequent treatment	15 (14.71)
Repeated TACE	45 (44.12)
Local tumor ablation	30 (29.41)
HAIC	11 (10.78)
Radiotherapy	9 (8.82)
Hepatectomy	8 (7.84)
Adoptive T cell transfer therapy	4 (3.92)
Liver transplantation	2 (1.96)

HAIC: Hepatic artery infusion chemotherapy; TACE: Transarterial chemoembolization.